CRBU Overview

Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. The Company is dedicated to developing transformative therapies for patients with devastating diseases. The Company's chRDNA genome-editing technology enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is focused on vispacabtagene regedleucel (vispa-cel) and CB-011 as off-the-shelf CAR-T cell therapies that have the potential to provide broad access and rapid treatment for patients with hematologic malignancies. Vispa-cel is an allogeneic anti-CD19 CAR-T cell therapy that has been evaluated in patients with relapsed or refractory B cell non-Hodgkin lymphoma. CB-011 is an allogeneic anti-BCMA CAR-T cell therapy that is being evaluated in patients with relapsed or refractory multiple myeloma.

Wall Street analysts forecast CRBU stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRBU is8.00 USD with a low forecast of 6.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Caribou Biosciences Inc revenue for the last quarter amounts to 2.40M USD, increased 1.87

Caribou Biosciences Inc. EPS for the last quarter amounts to -0.26 USD, decreased -39.53

Caribou Biosciences Inc (CRBU) has 97 emplpoyees as of June 20 2026.

Today CRBU has the market capitalization of 162.66M USD.